Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Virus elimination during the recycling of chromatographic columns used during the manufacture of coagulation factors.

Roberts PL.

Biologicals. 2014 Jul;42(4):184-90. doi: 10.1016/j.biologicals.2014.06.003. Epub 2014 Jun 26.

PMID:
24981392
2.

Virus elimination during the purification of monoclonal antibodies by column chromatography and additional steps.

Roberts PL.

Biotechnol Prog. 2014 Nov-Dec;30(6):1341-7. doi: 10.1002/btpr.1984. Epub 2014 Sep 12.

PMID:
25181429
4.

Inactivation and clearance of viruses during the manufacture of high purity factor IX.

Johnston A, Macgregor A, Borovec S, Hattarki M, Stuckly K, Anderson D, Goss NH, Oates A, Uren E.

Biologicals. 2000 Sep;28(3):129-36.

PMID:
10964439
5.

Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions.

Roberts PL, Feldman P, Crombie D, Walker C, Lowery K.

Biologicals. 2010 Mar;38(2):303-10. doi: 10.1016/j.biologicals.2009.12.006. Epub 2010 Jan 20.

PMID:
20089418
6.
7.

Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.

Roberts PL, Dunkerley C, Walker C.

Biologicals. 2012 Sep;40(5):345-52. doi: 10.1016/j.biologicals.2012.04.007. Epub 2012 May 30.

PMID:
22658506
8.

Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.

Roberts PL, Lloyd D, Marshall PJ.

Biologicals. 2009 Jan;37(1):26-31. doi: 10.1016/j.biologicals.2008.08.003. Epub 2008 Oct 10.

PMID:
18848782
9.

Issues in the development of medical products based on human plasma.

Josić D, Schulz P, Biesert L, Hoffer L, Schwinn H, Kordis-Krapez M, Strancar A.

J Chromatogr B Biomed Sci Appl. 1997 Jul 4;694(2):253-69. Review.

PMID:
9252039
10.

Chromatographic removal of viruses from plasma derivatives.

Burnouf T.

Dev Biol Stand. 1993;81:199-209. Review.

PMID:
8174804
11.
12.

Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.

Kim IS, Choi YW, Kang Y, Sung HM, Shin JS.

J Microbiol Biotechnol. 2008 May;18(5):997-1003.

13.
14.

Heat treatment at 100 degrees C of factor VIII and IX coagulation factor concentrates.

Teh LC, Woodfield DG.

Med J Aust. 1993 Sep 6;159(5):355-6. No abstract available. Erratum in: Med J Aust 1993 Nov 15;159(10):712.

PMID:
8361441
15.

Virus inactivation by protein denaturants used in affinity chromatography.

Roberts PL, Lloyd D.

Biologicals. 2007 Oct;35(4):343-7. Epub 2007 May 24.

PMID:
17517521
16.
17.
18.

Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.

Lemon SM, Murphy PC, Smith A, Zou J, Hammon J, Robinson S, Horowitz B.

J Med Virol. 1994 May;43(1):44-9.

PMID:
8083647
19.

Improvement of virus safety of an antihemophilc factor IX by virus filtration process.

Kim IS, Choi YW, Kang Y, Sung HM, Sohn KW, Kim YS.

J Microbiol Biotechnol. 2008 Jul;18(7):1317-25.

20.

Supplemental Content

Support Center